Stocks Health care GNTA
NASDAQ · Health careGenenta Science S.p.A. (GNTA)
It posted a net loss of €6.5M. In fiscal 2025 capital spending exceeded operating cash flow by €6.9M. At December 31, 2025 it held €5.5M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 1, 2026.
Key facts about Genenta Science S.p.A.
- Net worth
- Genenta Science S.p.A. has a market value (market cap) of $47.5M at the latest share price, and shareholders' equity of €21.8M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used €6.9M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on April 1, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Genenta Science S.p.A. does
Genenta Science S.p.A. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker GNTA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -€6.5M | -€0.33 | -€6.9M |
| 2024 | n/a | -€8.9M | -€0.49 | -€6.2M |
| 2023 | n/a | -€11.6M | -€0.64 | -€11.2M |
| 2022 | n/a | -€8.5M | -€0.47 | -€7.4M |
| 2021 | n/a | -€5.5M | -€0.37 | -€7M |
| 2021 | n/a | -€5.6M | n/a | -€6.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Genenta Science S.p.A. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 2, 2026Activist stake changed SCHEDULE 13D/A
- September 11, 2026
- September 2, 2026
- July 31, 2026
- July 14, 2026
- July 1, 2026
- June 26, 2026
- June 24, 2026
- June 17, 2026
- June 16, 2026
Insider trades
What the people running Genenta Science S.p.A. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns GNTA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Marco Nuzzo13D, may seek influence with 10 related filers | 11.5% | October 2, 2026 |
| Pierluigi Paracchi13G, passive | 9.8% | January 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 9 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Eurizon Capital SGR S.p.A. | 360,000 | 0 |
| Allianz SE | 234,050 | 0 |
| SmartHarvest Portfolios, LLC | 43,856 | -90,591 |
| Simplicity Wealth,LLC | 18,590 | +6,379 |
| Ground Swell Capital, LLC | 14,374 | new |
| GAMMA Investing LLC | 9,863 | -4,425 |
| UBS Group AG | 3,027 | -80 |
| Virtu Financial LLC | 36,913 | new |
| Farther Finance Advisors, LLC | 3 | 0 |
Insiders
Questions about GNTA
What does Genenta Science S.p.A. do?
Genenta Science S.p.A. is a company in the Health care sector, listed on NASDAQ as GNTA. Its shares trade on NASDAQ under the ticker GNTA.
What is Genenta Science S.p.A.'s net worth?
Genenta Science S.p.A. has a market value (market cap) of $47.5M at the latest share price, and shareholders' equity of €21.8M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Genenta Science S.p.A. profitable?
No. In fiscal 2025 it reported a net loss of €6.5M.
When did Genenta Science S.p.A. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 1, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the activist stake changed from October 2, 2026.
Similar companies
Compare GNTA with
Follow GNTA
Get an email when Genenta Science S.p.A. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Genenta Science S.p.A. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.